Repurposing the Dopamine Transporter Antagonist Vanoxerine to Treat Colorectal Cancer
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Xi Y, Xu P
. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021; 14(10):101174.
PMC: 8273208.
DOI: 10.1016/j.tranon.2021.101174.
View
2.
Kreso A, van Galen P, Pedley N, Lima-Fernandes E, Frelin C, Davis T
. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med. 2013; 20(1):29-36.
DOI: 10.1038/nm.3418.
View
3.
OBrien C, Pollett A, Gallinger S, Dick J
. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2006; 445(7123):106-10.
DOI: 10.1038/nature05372.
View
4.
Preti A
. Vanoxerine National Institute on Drug Abuse. Curr Opin Investig Drugs. 2001; 1(2):241-51.
View
5.
Prabhu V, Allen J, Dicker D, El-Deiry W
. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner. Cancer Res. 2015; 75(7):1423-32.
PMC: 4537643.
DOI: 10.1158/0008-5472.CAN-13-3451.
View